Sunday, September 27, 2026

Sorrento Therapeutics Stock Bearish Momentum With A 16% Slide In The Last 5 Sessions

Sorrento Therapeutics Stock Bearish Momentum With A 16% Slide In The Last 5 Sessions

(VIANEWS) - Shares of Sorrento Therapeutics (NASDAQ: SRNE) slid by a staggering 16.22% in 5 sessions from $0.37 at -16.22, to $0.31 at 23:23 EST on Wednesday, after five sequential sessions in a row of losses. NASDAQ is falling 0.85% to $11,929.34, after three sequential sessions in a row of losses.

Sorrento Therapeutics's last close was $0.35, 88.82% below its 52-week high of $3.09.

About Sorrento Therapeutics

Earnings Per Share

As for profitability, Sorrento Therapeutics has a trailing twelve months EPS of $-1.3.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -378.92%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Sorrento Therapeutics's stock is considered to be overbought (>=80).

Moving Average

Sorrento Therapeutics's value is way below its 50-day moving average of $0.77 and way below its 200-day moving average of $1.55.

Sales Growth

Sorrento Therapeutics's sales growth is 32.2% for the present quarter and 8.8% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 44.3%, now sitting on 60.32M for the twelve trailing months.

More news about Sorrento Therapeutics (SRNE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com